Evaluation and statistical analysis of the database of prostate bi̇opsy with transrectal ultrasound guidance in our clinic

Objective: We aimed to retrospectively analyze the data of 2000 benign patients who underwent transrectal prostate biopsy between 2000 and 2024 and to compare our rates with the current literature, to add 2000 disease data to the literature and to conduct new researches from the database obtained. Materials and Methods: After the approval decision of Manisa Celal Bayar University Hospital Health Sciences Ethics Committee with the number 20478486/2483, the data of our patients who underwent prostate biopsy between 2000 and 2024 from our prostate biopsy database were retrospectively analyzed. Age, PSA value, prostate volumes, rectal touch findings, alcohol and smoking, comorbidities (history of angiography, diabetes mellitus, hypertension, atrial fibrillation, chronic renal failure, urinary system stone disease), pain scale during the procedure, presence of post-procedural fever and sepsis, minor post-procedural complications (hematuria, rectal bleeding, hematospermia, urinary retention), Percentages and averages of prophylactic antibiotic group, urologic history (family history of prostate cancer, history of TUR-prostate, history of benign prostatic hyperplasia, history of alpha blocker use), number of cores taken in biopsy, lower urinary tract symptoms, IPSS scores, MR prostate volume and its relation with TRUS-measured PV values, and presence of rebiopsy were extracted. Results: The study included 2000 patients. The mean age was 65.69 years. 14% were active smokers, 0.7% were regular alcohol drinkers, 15.9% had diabetes mellitus, 19.3% hypertension, 13% angiography, 0.3% atrial fibrillation, 1.4% chronic renal failure, 12.1% had anticoagulant use, 6.4% had a history of urinary tract stone disease, 13.5% had BPH, 19.8% had alpha blocker drug use, and 6.9% had a history of TUR-P. In 1834 patients, the mean prostate volume measured by ultrasound was 45.32 cc, while the mean prostate volume measured by MRI was 56.40 cc in 383 patients. When the prostate volume measurements in TRUS imaging of 383 patients with MR imaging and prostate volume measurements were analyzed statistically, it was calculated that 316 (83%) patients were similar to± 5-10 cc volume, 38 (9%) patients differed from± 20-40 cc volume and 29 (8%) patients differed from± >40 cc volume. While the mean PSA value was 15.68 ng/ml, when analyzed in terms of pain scale, the mean RAS value was 2.1 and the mean BAS value was 1.27. PRM findings were malignant in 12% of the patients. While 5.2% of the patients had hospitalization due to fever after the procedure, 0.15% had sepsis. There was no mortality. 0.08% had hematuria, 0.7% had rectal bleeding, 1.7% had urinary retention, and 5.6% had hematospermia. 27% of the patients received prophylaxis from cephalosporin group, 70% from quinolone group and 3% from other antibiotic groups. 12 core biopsies were obtained from 85'5% of the patients. 14% of the patients were rebiopsy patients and their pathology was coded as benign prostatic hyperplasia Conclusion: When we compared our complication rates with the literature, we found similar rates with many studies. Although there are multicenter studies on transrectal prostate biopsy with a large number of patients, the number of these studies is small. The data of 2000 patients in our clinic will contribute to the literature and new studies with patient characteristics. Keywords: Benign, comorbidity, minor complications, sepsis, pain, transrectal prostate biopsy